Antibody-drug conjugate shows promising safety and response rates for patients with rare blood cancer

Published Date: 03 Jun 2025

The first-in-class antibody-drug conjugate (ADC) pivekimab sunirine (PVEK) demonstrated promising efficacy and high response rates for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), according to data ...

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Novel Treatment Shows Promise for Oral Mucositis Caused by Radiation.

2.

Exercise may help breast cancer survivors manage weight

3.

Reasons Behind Refusing Stem Cell Transplantation in Certain Myeloma Patients.

4.

Adding SBRT to systemic therapy could boost outcomes for some locally advanced hepatocellular carcinoma patients

5.

In cancer patients taking immune checkpoint inhibitors, systematic vitamin D supplementation improves outcomes.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot